MAKO SURGICAL CLOSES $20 MILLION IN SERIES B FUNDING

MAKO Surgical Corp., an emerging medical technology company targeting the $4 billion and rapidly growing knee replacement medical device sector, announced today that it has closed on a $20 million Series B round of private equity financing. Participants in the financing round included funds to which MDS Capital provides services, The Exxel Group, Aperture Venture Partners, MediTech Advisors, Ivy Capital Partners, Sycamore Ventures and existing MAKO investors. MAKO's proprietary solution, called Makoplasty(TM), targets early stage knee therapies and goes beyond traditional minimally invasive procedures to enable rapid patient recovery and improved anatomical functionality. MAKO's revolutionary technology enables a surgeon to digitally sculpt and preserve bone tissue through small portals in a highly reproducible and simple manner.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050808005701&newsLang=en)